Gene Therapy Player Amicus Therapeutics Terminates SPAC Merger, Shares Fall
Amicus Therapeutics Inc (NASDAQ: FOLD) has terminated its plans to spin off its gene therapy assets, citing 'existing market conditions.'
Perceptive Advisors-Backed SPAC To Acquire Amicus’s Gene Therapy Business
Amicus Therapeutics Inc (NASDAQ:FOLD) has agreed to spin off its gene therapy business to Sciences Acquisition Corp IV (NASDAQ:ARYD) and launch genetic medicine…
The Daily Biotech Pulse: AbbVie’s Migraine Drug OK’d By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours.
Click here for accessing Benzinga's FDA Calendar
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 28)
